Education
| School ¡X Major ¡X Degree | Duration |
|---|---|
|
°ê¥ß°ê¨¾Âå¾Ç°| ¡X Âå¾Ç¬ì¾Ç¬ã¨s©Ò(²¦) ¡X ³Õ¤h Doctorate, , |
2004/09 ¡X 2012/06 |
|
°ê¥ß²MµØ¤j¾Ç ¡X ¥Í©R¬ì¾Ç¨t(²¦) ¡X ºÓ¤h Master, , |
1999/09 ¡X 2001/06 |
|
°ê¥ß¤¤¤s¤j¾Ç ¡X ¥Íª«¬ì¾Ç¨t(²¦) ¡X ¾Ç¤h Bachelor, , |
1995/09 ¡X 1999/06 |
Intramural Experience
| Office/Department/Institute | Position | Duration |
|---|---|---|
| ¬ã¨sµo®i³B¹êÅç°Êª«¤¤¤ß Center for Laboratory Animals | Director | 2025/08/01 ¡X 2026/07/31 |
| ·L¥Íª«º[§K¬Ì¾Ç¬ì Department of Microbiology & Immunology | Associate Professor | 2022/02/01 ¡X |
| ·L¥Íª«º[§K¬Ì¾Ç¬ì Department of Microbiology & Immunology | Assistant Professor | 2016/02/01 ¡X 2022/01/31 |
Extramural Experience
Discipline
| NO | Discipline | Expertise |
|---|---|---|
| 1 | ¥Íª«Âå¹AÃþ Biology, Medicine and Agriculture | ·L¥Íª«¤Î§K¬Ì¾Ç Microbiology and Immunology |
Research & Technology Platform Open to the Outside
Interested Area(s)for Interdisciplinary Research
¦ÛÅé§K¬Ì¾Ç¡BG¸z¹D§K¬Ì¾Ç¡B¸~½F§K¬Ì¾Ç
Area(s) of Expertise & Research
¦ÛÅé§K¬Ì¾Ç¡BG¸z¹D§K¬Ì¾Ç¡B¸~½F§K¬Ì¾Ç¦ÛÅé§K¬Ì¾Ç¤Î¸~½F§K¬Ì¾Ç
Autoimmunology and tumor immunology
Publication
| NO | Publication |
|---|---|
| 1 | Clostridium butyricumMIYAIRI 588 Reduces Colorectal Adenomatous Polyp Recurrence: A Randomized Crossover Trial Clostridium butyricumMIYAIRI 588 Reduces Colorectal Adenomatous Polyp Recurrence: A Randomized Crossover Trial |
| 2 | Polycyclic aromatic hydrocarbon aggravates high-fat diet-induced metabolic dysfunction-associated steatotic liver disease through disturbing hepatocyte sphingolipid metabolism. Polycyclic aromatic hydrocarbon aggravates high-fat diet-induced metabolic dysfunction-associated steatotic liver disease through disturbing hepatocyte sphingolipid metabolism. |
| 3 | Macrophage MRC2 Deficiency Mitigates HFD-Induced MASLD by Downregulating CD147-Regulated TNF-£\ Production Macrophage MRC2 Facilitates MASLD via the CD147-TNF-£\ Axis Macrophage MRC2 Deficiency Mitigates HFD-Induced MASLD by Downregulating CD147-Regulated TNF-£\ Production Macrophage MRC2 Facilitates MASLD via the CD147-TNF-£\ Axis |
| 4 | Corrigendum: Arsenic exposure and lung fibrotic changes-evidence from a longitudinal cohort study and experimental models. Corrigendum: Arsenic exposure and lung fibrotic changes-evidence from a longitudinal cohort study and experimental models. |
| 5 | The GLP-1 receptor agonist exenatide ameliorates neuroinflammation, locomotor activity, and anxiety-like behavior in mice with diet-induced obesity through the modulation of microglial M2 polarization and downregulation of SR-A4. The GLP-1 receptor agonist exenatide ameliorates neuroinflammation, locomotor activity, and anxiety-like behavior in mice with diet-induced obesity through the modulation of microglial M2 polarization and downregulation of SR-A4. |
| 6 | S100A6 participates in initiation of autoimmune encephalitis and is under epigenetic control S100A6 participates in initiation of autoimmune encephalitis and is under epigenetic control |
| 7 | Copper Exposure Induces Epithelial-Mesenchymal Transition-Related Fibrotic Change via Autophagy and Increase Risk of Lung Fibrosis in Human Copper Exposure Induces Epithelial-Mesenchymal Transition-Related Fibrotic Change via Autophagy and Increase Risk of Lung Fibrosis in Human |
| 8 | HCV Core Protein-ISX Axis Promotes Chronic Liver Disease Progression via Metabolic Remodeling and Immune Suppression. HCV Core Protein-ISX Axis Promotes Chronic Liver Disease Progression via Metabolic Remodeling and Immune Suppression. |
| 9 | Aryl hydrocarbon receptor-kynurenine axis promotes oncogenic activity in BCP-ALL. Aryl hydrocarbon receptor-kynurenine axis promotes oncogenic activity in BCP-ALL. |
| 10 | Arsenic exposure and lung fibrotic changes-evidence from a longitudinal cohort study and experimental models. Arsenic exposure and lung fibrotic changes-evidence from a longitudinal cohort study and experimental models. |
| 11 | Reciprocal Regulation of Cancer-Associated Fibroblasts and Tumor Microenvironment in Gastrointestinal Cancer: Implications for Cancer Dormancy. Reciprocal Regulation of Cancer-Associated Fibroblasts and Tumor Microenvironment in Gastrointestinal Cancer: Implications for Cancer Dormancy. |
| 12 | °w¹ïÀù¯g¬ÛÃö¦¨ÅÖºû²ÓM¹ï§Ü®ø¤Æ¨t²Î¸~½F¶i®iªº¤ÑµM¤Æ¦Xª«¡GªvÀø¨£¸Ñ Natural compounds targeting cancer-associated fibroblasts against digestive system tumor progression: Therapeutic insights |
| 13 | ¨â¦W¥ý¤Ñ©Ê°Æ¦Ù±jª½±wªÌ¬ðÅÜ Nav1.4 ³q¹Dªº¶u¹q¬y´_µdªº°Ê¤O¾Ç§ïÅÜ Kinetic alterations in resurgent sodium currents of mutant Nav1.4 channel in two patients affected by paramyotonia con-genita |
| 14 | Blimp-1 moulds the epigenetic architecture of IL-21-mediated autoimmune diseases through an autoregulatory circuit Blimp-1 moulds the epigenetic architecture of IL-21-mediated autoimmune diseases through an autoregulatory circuit |
| 15 | Effects of Montelukast on Arsenic-Induced Epithelial-Mesenchymal Transition and the Role of Reactive Oxygen Species Production in Human Bronchial Epithelial Cells. Effects of Montelukast on Arsenic-Induced Epithelial-Mesenchymal Transition and the Role of Reactive Oxygen Species Production in Human Bronchial Epithelial Cells. |
| 16 | The efficacy of culture-guided versus empirical therapy with high-dose proton pump inhibitor as third-line treatment of Helicobacter pylori infection: A real-world clinical experience. The efficacy of culture-guided versus empirical therapy with high-dose proton pump inhibitor as third-line treatment of Helicobacter pylori infection: A real-world clinical experience. |
| 17 | Suppressive Effects of 4-(Phenylsulfanyl) Butan-2-One on CCL-1 Production via Histone Acetylation in Monocytes. Suppressive Effects of 4-(Phenylsulfanyl) Butan-2-One on CCL-1 Production via Histone Acetylation in Monocytes. |
| 18 | Immunological map in COVID-19. Immunological map in COVID-19. |
| 19 | WLS/wntless ¦b³q¹L WNT «H¸¹¿W¥ß¾÷¨î±±¨î¾ð¬ð²ÓMúA¤è±¦ÜÃö«n WLS/wntless is essential in controlling dendritic cell homeostasis via a WNT signaling-independent mechanism |
| 20 | Hyperbaric Oxygen Therapy Alleviates the Autoimmune Encephalomyelitis via the Reduction of IL-17a and GM-Csf Production of Autoreactive T Cells as Well as Boosting the Immunosuppressive IL-10 in the Central Nervous System Tissue Lesions Hyperbaric Oxygen Therapy Alleviates the Autoimmune Encephalomyelitis via the Reduction of IL-17a and GM-Csf Production of Autoreactive T Cells as Well as Boosting the Immunosuppressive IL-10 in the Central Nervous System Tissue Lesions |
| 21 | SPAK Deficiency Attenuates Chemotherapy-Induced Intestinal Mucositis SPAK Deficiency Attenuates Chemotherapy-Induced Intestinal Mucositis |
| 22 | ©ö¶g¿}ª`®g¾¯½Õ¸`¤¤¼Ï¯«¸g¨t²Î¤¤²Õ´®û¼íTh1/Th17²ÓMªºµo¨|©MP¸£ª¢Th1²ÓMªºP¯f©Ê Dulaglutide modulates the development of tissue-infiltrating Th1/Th17 cells and the pathogenicity of encephalitogenic Th1 cells in the Central Nervous System |
| 23 | Immunopathological effects of Agaricus blazei Murill polysaccharides against Schistosoma mansoni infection by Th1 and NK1 cells differentiation Immunopathological effects of Agaricus blazei Murill polysaccharides against Schistosoma mansoni infection by Th1 and NK1 cells differentiation |
| 24 | S100A6 «P¶i B ²O¤Ú²ÓM³q¹L¦Û¨§K¬Ì©Ê¸£ª¢ªº¦å¸£«Ì»Ùº¯³z S100A6 Promotes B Lymphocyte Penetration Through the Blood-Brain Barrier in Autoimmune Encephalitis |
| 25 | «ÕªùÁ³±Û±ìµßÂǶ¡½è²ÓM¤§COLEC12, PGE2-EP2/4,©óG¬ÛÃö¯e¯f©Ò§êºt¤§¥ý¤Ñ§K¬Ì¤ÏÀ³ Stromal C-type lectin receptor COLEC12 integrates H. pylori, PGE2-EP2/4 axis and innate immunity in gastric diseases |
| 26 | ¶Ü°Ø³z¹L¤W½ÕConnexin 43ªí¹F¨Ó»¤¾É¦¨ÅÖºû²ÓM¬¡¤Æ: ³Ð¶Ë¡¦X¤¤ÅÖºû¤Æªº·N¸q Morphine Induces Fibroblast Activation through Up-regulation of Connexin 43 Expression: Implication of Fibrosis in Wound Healing |
| 27 | Pentachloropseudilin³q¹L¥[³t¹v²ÓM¤¤²ÓMªí±II«¬TGF-£]¨üÅ骺Âà´«¨Ó§í¨îÂà¤Æ¥Íªø¦]¤l-£]¡]TGF-£]¡^¬¡©Ê Pentachloropseudilin Inhibits Transforming Growth Factor-£] (TGF-£]) Activity by Accelerating Cell-Surface Type II TGF-£] Receptor Turnover in Target Cells |
| 28 | Role of glycine N-methyltransferase in the regulation of T-cell responses in experimental autoimmune encephalomyelitis Role of glycine N-methyltransferase in the regulation of T-cell responses in experimental autoimmune encephalomyelitis |
| 29 | Glucosamine modulates T cell differentiation through downregulating N-linked glycosylation of CD25 Glucosamine modulates T cell differentiation through downregulating N-linked glycosylation of CD25 |
| 30 | Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses |
| 31 | DDX3X Biomarker Correlates with Poor Survival in Human Gliomas DDX3X Biomarker Correlates with Poor Survival in Human Gliomas |
| 32 | Targeting tumor necrosis factor receptor 1 assembly reverses Th17-mediated colitis through boosting a Th2 response Targeting tumor necrosis factor receptor 1 assembly reverses Th17-mediated colitis through boosting a Th2 response |
| 33 | T cell-specific BLIMP-1 deficiency exacerbates experimental autoimmune encephalomyelitis in non-obese diabetic mice by increasing Th1 and Th17 cells T cell-specific BLIMP-1 deficiency exacerbates experimental autoimmune encephalomyelitis in non-obese diabetic mice by increasing Th1 and Th17 cells |
| 34 | Overexpression of Galectin-9 in Islets Prolongs Grafts Survival via Downregulation of Th1 Responses Overexpression of Galectin-9 in Islets Prolongs Grafts Survival via Downregulation of Th1 Responses |
| 35 | Different Modulation of Ptpn22 in Effector and Regulatory T Cells Leads to Attenuation of Autoimmune Diabetes in Transgenic Nonobese Diabetic Mice Different Modulation of Ptpn22 in Effector and Regulatory T Cells Leads to Attenuation of Autoimmune Diabetes in Transgenic Nonobese Diabetic Mice |
| 36 | B lymphocyte-induced maturation protein 1 (BLIMP-1) attenuates autoimmune diabetes in NOD mice by suppressing Th1 and Th17 cells B lymphocyte-induced maturation protein 1 (BLIMP-1) attenuates autoimmune diabetes in NOD mice by suppressing Th1 and Th17 cells |
| 37 | Molecular and functional studies of tilapia (Oreochromis mossambicus) NMDA receptor NR1 subunits Molecular and functional studies of tilapia (Oreochromis mossambicus) NMDA receptor NR1 subunits |
| 38 | Identification of the substrates and interaction proteins of aurora kinases from a protein-protein interaction model Identification of the substrates and interaction proteins of aurora kinases from a protein-protein interaction model |
Project
| NO |
YEAR ¡X Source ¡X No ¡X Type
Project Name
|
Duration |
|---|---|---|
| 1 |
113 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSTC113-2314-B-037-044 ¡X 1 Ó¤H«¬
¬ã¨sGÀùªº¥ÌÅS¿}¨üÅé¦b½Õ±±¸~½F·LÀô¹Ò§K¬Ì¶ì§ÎªºÃöÁä¼vÅT( )
|
2024/08/01 ~ 2025/07/31 |
| 2 |
113 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X NSTC114-2813-C-037-007-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
114¦~«×¤j±M¾Ç¥Í¬ã¨spµe-Ĭ¤lÞ±(Âå¾Ç3)( )
|
2025/07/01 ~ 2026/02/28 |
| 3 |
112 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSTC112-2314-B-037-093 ¡X 1 Ó¤H«¬
¬ã¨s¥ÌÅS¿}¨üÅé½Õ¸`«Iŧ©ÊGÀù²ÓM¤ÀªcÁͤƿE¯À¤Î§@¥Î©ó¸~½F·LÀô¹Ò§K¬Ì¶ì§ÎªºÃöÁ䨤¦â( )
|
2023/08/01 ~ 2024/07/31 |
| 4 |
112 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSTC112-2320-B-037-005 ¡X 2 ¾ã¦X«¬
¬ã¨s¸z¹D¯S²§©Ê¦P·½½c(intestine-specific homeobox ;ISX)-»¤¾Éªº¯×½è¥NÁÂ¥¢¿Å¦bºC©Ê¨x¯fªº¼vÅT-¬ã¨s¸z¹D¯S²§©Ê¦P·½½c-¥ÌÅS¿}¨üÅé¶b½u¦b°ª¯×ªÕ¶¼¹»¤¾É«D°sºë©Ê¯×ªÕ¨x¯e¯f¶i®i¤¤¹ï©ó¨x²ÓM¯×ªÕ»Ä¥NÁ©M¥¨¾½²ÓM¥\¯àªº½Õ¸`¼vÅT(3/3)( )
|
2023/08/01 ~ 2024/07/31 |
| 5 |
111 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST109-2314-B-037-034-MY3 ¡X 1 Ó¤H«¬
¬ã¨sMRC2¦bGÀù¥Í¦¨¹Lµ{¤¤ªº¤À¤l¾÷Âà:±qÁ{§É¦Ü°ò¦ªºåªR(3/3)( )
|
2022/08/01 ~ 2023/07/31 |
| 6 |
111 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST111-2320-B-037-032 ¡X 2 ¾ã¦X«¬
¬ã¨s¸z¹D¯S²§©Ê¦P·½½c(intestine-specific homeoboxISX)-»¤¾Éªº¯×½è¥NÁÂ¥¢¿Å¦bºC©Ê¨x¯fªº¼vÅT-¬ã¨s¸z¹D¯S²§©Ê¦P·½½c-¥ÌÅS¿}¨üÅé¶b½u¦b°ª¯×ªÕ¶¼¹»¤¾É«D°sºë©Ê¯×ªÕ¨x¯e¯f¶i®i¤¤¹ï©ó¨x²ÓM¯×ªÕ»Ä¥NÁ©M¥¨¾½²ÓM¥\¯àªº½Õ¸`¼vÅT(2/3)( )
|
2022/08/01 ~ 2023/07/31 |
| 7 |
110 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST109-2314-B-037-034-MY3 ¡X 1 Ó¤H«¬
¬ã¨sMRC2¦bGÀù¥Í¦¨¹Lµ{¤¤ªº¤À¤l¾÷Âà:±qÁ{§É¦Ü°ò¦ªºåªR(2/3)( )
|
2021/08/01 ~ 2023/07/31 |
| 8 |
110 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST110-2320-B-037-009 ¡X 2 ¾ã¦X«¬
¬ã¨s¸z¹D¯S²§©Ê¦P·½½c(intestine-specific homeobox ISX)-»¤¾Éªº¯×½è¥NÁÂ¥¢¿Å¦bºC©Ê¨x¯fªº¼vÅT-¬ã¨s¸z¹D¯S²§©Ê¦P·½½c-¥ÌÅS¿}¨üÅé¶b½u¦b°ª¯×ªÕ¶¼¹»¤¾É«D°sºë©Ê¯×ªÕ¨x¯e¯f¶i®i¤¤¹ï©ó¨x²ÓM¯×ªÕ»Ä¥NÁ©M¥¨¾½²ÓM¥\¯àªº½Õ¸`¼vÅT(1/3)( )
|
2021/08/01 ~ 2022/07/31 |
| 9 |
110 ¡X NK °ªÂå-¤¤¤s¦X§@pµe ¡X ¡X 1 Ó¤H«¬
ÄÄ©ú¥ÌÅS¿}¨üÅé¦bGÀù¥Íªøªº¼ç¦b¤À¤l¾÷( )
|
2021/01/01 ~ 2021/12/31 |
| 10 |
110 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X MOST111-2813-C-037-075-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
111¦~«×¤j±M¾Ç¥Í¬ã¨spµe-Áé¼ä©ý(©I§l3)( )
|
2022/07/01 ~ 2023/02/28 |
| 11 |
109 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST109-2314-B-037-034-MY3 ¡X 1 Ó¤H«¬
¬ã¨sMRC2¦bGÀù¥Í¦¨¹Lµ{¤¤ªº¤À¤l¾÷Âà:±qÁ{§É¦Ü°ò¦ªºåªR(1/3)( )
|
2020/08/01 ~ 2023/07/31 |
| 12 |
109 ¡X NK °ªÂå-¤¤¤s¦X§@pµe ¡X NSYSUKMU109-I004-2 ¡X 2 ¾ã¦X«¬
Explore how ANE influence macrophages to promote the initiation and progression of oral cancer( )
|
2020/01/01 ~ 2020/12/31 |
| 13 |
109 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X HS1100622001-1 ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
110¦~«×°]¹Îªk¤H°·±d¬ì¾Ç¤å±Ð°òª÷·|Âå¾Ç¨t¾Ç¥Í´»´Á¬ã¨spµe--ªô«a»T(Âå¾Ç3)( )
|
2021/07/01 ~ 2021/09/30 |
| 14 |
109 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X MOST110-2813-C-037-017-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
110¦~«×¤j±M¾Ç¥Í¬ã¨spµe-®]µE²b(¥Í§Þ3)( )
|
2021/07/01 ~ 2022/02/28 |
| 15 |
108 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST108-2320-B-037-003-MY2 ¡X 1 Ó¤H«¬
åªRÂà¿ý¦]¤lBlimp-1¤Î¨ä«áÂàĶ׹¢¥\¯à¹ï¦ÛÅé§K¬Ì©Ê¸£¯áÅ誢¯e¯f¼Ò¦¡¤¤½Õ±±¾AÀ³©Ê§K¬Ì¥\¯àªº¤À¤l¾÷Âà(2/2)( )
|
2020/05/01 ~ 2020/10/31 |
| 16 |
108 ¡X NK °ªÂå-¤¤¤s¦X§@pµe ¡X NSYSUKMU108-I005-1 ¡X 2 ¾ã¦X«¬
pentabromopseudilinÃþ¤ÑµMª«¦b§í¨îTGF-£]§@¥Î¤§¾÷Âà±´°Q( )
|
2019/01/01 ~ 2019/12/31 |
| 17 |
108 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X HS1090622003-1 ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
109¦~«×°]¹Îªk¤H°·±d¬ì¾Ç¤å±Ð°òª÷·|Âå¾Ç¨t¾Ç¥Í´»´Á¬ã¨spµe--¶À¬RºÍ(Âå¾Ç4)( )
|
2020/07/01 ~ 2020/09/30 |
| 18 |
107 ¡X NK °ªÂå-¤¤¤s¦X§@pµe ¡X NSYSUKMU107-I001-1 ¡X 2 ¾ã¦X«¬
pentachloropseudilinÃþ¤ÑµMª«¦b§í¨îTGF-B§@¥Î¤§¾÷Âà±´°Q( )
|
2018/01/01 ~ 2018/12/31 |
| 19 |
107 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST108-2320-B-037-003-MY2 ¡X 1 Ó¤H«¬
åªRÂà¿ý¦]¤lBlimp-1¤Î¨ä«áÂàĶ׹¢¥\¯à¹ï¦ÛÅé§K¬Ì©Ê¸£¯áÅ誢¯e¯f¼Ò¦¡¤¤½Õ±±¾AÀ³©Ê§K¬Ì¥\¯àªº¤À¤l¾÷Âà(1/2)( )
|
2019/05/01 ~ 2020/10/31 |
| 20 |
106 ¡X NK °ªÂå-¤¤¤s¦X§@pµe ¡X ¡X 2 ¾ã¦X«¬
¥H¸zª¢¹êÅç°Êª«¼Ò¦¡±´°Q·Í¤Æ¹TÓi»ÄÃþ(bromotryrosine)®ü¬v¤ÑµMª«¤§§@¥Î¤Î§K¬Ì½Õ¸`¾÷Âà( )
|
2017/01/01 ~ 2017/12/31 |
| 21 |
106 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST104-2321-B-037-003-MY3 ¡X 1 Ó¤H«¬
¬ã¨sc-Maf¤Î¨ä«áÂàĶ׹¢¥\¯à¹ï¦ÛÅé§K¬Ì©Ê¸£¯áÅ誢¤§§K¬Ì½Õ±±¨¤¦â»Pµo®i·s¿oªº°ò¦]ªvÀøµ¦²¤:¥H³Ð·sªº°ò¦]Âà´Þ¤Î°ò¦]´î®z¤p¹«¼Ò¦¡åªR¤§(3/3)( )
|
2017/08/01 ~ 2019/07/31 |
| 22 |
106 ¡X Q ·s¸u±Ð®vpµe(®Õ¤º) ¡X KMU-Q107008 ¡X
åªRÂà¿ý¦]¤lBlimp-1¤Î¨ä«áÂàĶ׹¢¥\¯à¹ï¦ÛÅé§K¬Ì©Ê¸£¯áÅ誢¯e¯f¼Ò¦¡¤¤½Õ±±¾AÀ³©Ê§K¬Ì¥\¯àªº¤À¤l¾÷Âà( )
|
2018/01/01 ~ 2018/12/31 |
| 23 |
106 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X HS1070622008-1 ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
107¦~«×°]¹Îªk¤H°·±d¬ì¾Ç¤å±Ð°òª÷·|Âå¾Ç¨t¾Ç¥Í´»´Á¬ã¨spµe--ªL®x·N(Âå¾Ç3)( )
|
2018/07/01 ~ 2018/09/30 |
| 24 |
105 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST104-2321-B-037-003-MY3 ¡X 1 Ó¤H«¬
¬ã¨sc-Maf¤Î¨ä«áÂàĶ׹¢¥\¯à¹ï¦ÛÅé§K¬Ì©Ê¸£¯áÅ誢¤§§K¬Ì½Õ±±¨¤¦â»Pµo®i·s¿oªº°ò¦]ªvÀøµ¦²¤:¥H³Ð·sªº°ò¦]Âà´Þ¤Î°ò¦]´î®z¤p¹«¼Ò¦¡åªR¤§(2/3)( )
|
2016/08/01 ~ 2019/07/31 |
| 25 |
105 ¡X Q ·s¸u±Ð®vpµe(®Õ¤º) ¡X KMU-Q106002 ¡X
¬ã¨s Blimp-1 ¤Î¨ä«áÂàĶ׹¢¥\¯à¹ïGM-CSF°ò¦]½Õ±±¤§¾÷Âà¨Ã«Øºc°ò¦]Âà´Þ¤p¹«¤§¦ÛÅé§K¬Ì©Ê¸£¯áÅ誢ªº¯e¯f¼Ò¦¡( )
|
2017/01/01 ~ 2017/12/31 |
| 26 |
105 ¡X TP ³»¦ypµe(°ªÂå) ¡X KMU-TP105PR18 ¡X
¬ã¨sT²ÓMªºBlimp-1°ò¦]¹ï©ó°ª¯×ªÕ¶¼¹©Ò¤Þ°_¯Ø®q¯Àªý§Ü©M²Ä¤G«¬¿}§¿¯fµ{ªº¼vÅT( )
|
2017/03/01 ~ 2017/10/31 |
| 27 |
105 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X MOST106-2813-C-037-015-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
106¦~«×¤j±M¾Ç¥Í¬ã¨spµe-³¯©É¿o(¤½½Ã2)( )
|
2017/07/01 ~ 2018/02/28 |
| 28 |
104 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST104-2321-B-037-003-MY3 ¡X 1 Ó¤H«¬
¬ã¨sc-Maf¤Î¨ä«áÂàĶ׹¢¥\¯à¹ï¦ÛÅé§K¬Ì©Ê¸£¯áÅ誢¤§§K¬Ì½Õ±±¨¤¦â»Pµo®i·s¿oªº°ò¦]ªvÀøµ¦²¤:¥H³Ð·sªº°ò¦]Âà´Þ¤Î°ò¦]´î®z¤p¹«¼Ò¦¡åªR¤§(1/3)( )
|
2016/02/01 ~ 2019/07/31 |
| 29 |
104 ¡X TP ³»¦ypµe(°ªÂå) ¡X KMU-TP104PR17 ¡X
To investigate the impacts of c-Maf SUMOylation in the IL-23- and IL-27- modulated T cell encephalitogenicity during the pathogenic processes of EAE( )
|
2016/04/01 ~ 2016/09/30 |
Patent
| NO | Patent Name | Country | Certified Date | Patent No |
|---|---|---|---|---|
| 1 | ¥Î©óªvÀø¯~»¤µo¤§ªÍ¥\¯à·l¶Ë¤§Ãþ¶Àà¬ÃĪ« | ¤¤µØ¥Á°ê | 2023/10/11 | I818466 |
| 2 | ¥Î©óªvÀø¡B¹w¨¾©Î´î»´ªÍ¥\¯à·l¶Ë¤§Ãþ¶Àà¬ÃĪ« | ¤¤µØ¥Á°ê | 2025/02/11 | I872951 |